Literature DB >> 20511189

Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology.

Kimberly R Porter1, Bridget J McCarthy, Sally Freels, Yoonsang Kim, Faith G Davis.   

Abstract

Prevalence is the best indicator of cancer survivorship in the population, but few studies have focused on brain tumor prevalence because of previous data limitations. Hence, the full impact of primary brain tumors on the healthcare system in the United States is not completely described. The present study provides an estimate of the prevalence of disease in the United States, updating an earlier prevalence study. Incidence data for 2004 and survival data for 1985-2005 were obtained by the Central Brain Tumor Registry of the United States from selected regions, modeled under 2 different survival assumptions, to estimate prevalence rates for the year 2004 and projected estimates for 2010. The overall incidence rate for primary brain tumors was 18.1 per 100 000 person-years with 2-, 5-, 10-, and 20-year observed survival rates of 62%, 54%, 45%, and 30%, respectively. On the basis of the sum of nonmalignant and averaged malignant estimates, the overall prevalence rate of individuals with a brain tumor was estimated to be 209.0 per 100 000 in 2004 and 221.8 per 100 000 in 2010. The female prevalence rate (264.8 per 100 000) was higher than that in males (158.7 per 100 000). The averaged prevalence rate for malignant tumors (42.5 per 100 000) was lower than the prevalence for nonmalignant tumors (166.5 per 100 000). This study provides estimates of the 2004 (n = 612 770) and 2010 (n = 688 096) expected number of individuals living with primary brain tumor diagnoses in the United States, providing more current and robust estimates for aiding healthcare planning and patient advocacy for an aging US population.

Entities:  

Mesh:

Year:  2010        PMID: 20511189      PMCID: PMC2940648          DOI: 10.1093/neuonc/nop066

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  18 in total

1.  The prevalence of cancer in Sweden 1984.

Authors:  H O Adami; T Gunnarsson; P Sparén; G Eklund
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

2.  The contribution of nonmalignant tumors to CNS tumor incidence rates among children in the United States.

Authors:  J G Gurney; D A Wall; P J Jukich; F G Davis
Journal:  Cancer Causes Control       Date:  1999-04       Impact factor: 2.506

3.  Cancer prevalence estimates based on tumour registry data in the Surveillance, Epidemiology, and End Results (SEER) Program.

Authors:  R M Merrill; R Capocaccia; E J Feuer; A Mariotto
Journal:  Int J Epidemiol       Date:  2000-04       Impact factor: 7.196

4.  Cancer prevalence in the UK: results from the EUROPREVAL study.

Authors:  D Forman; D Stockton; H Møller; M Quinn; P Babb; R De Angelis; A Micheli
Journal:  Ann Oncol       Date:  2003-04       Impact factor: 32.976

5.  Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries.

Authors:  J Lee Villano; Jennifer M Propp; Kimberly R Porter; Andrew K Stewart; Tibor Valyi-Nagy; Xinyu Li; Herbert H Engelhard; Bridget J McCarthy
Journal:  Neuro Oncol       Date:  2008-02-20       Impact factor: 12.300

6.  Brain tumors in children: long-term survival after radiation treatment.

Authors:  D Jenkin; M Greenberg; H Hoffman; B Hendrick; R Humphreys; A Vatter
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-02-01       Impact factor: 7.038

7.  Estimating cancer prevalence using mixture models for cancer survival.

Authors:  Norman Phillips; Andrew Coldman; Mary L McBride
Journal:  Stat Med       Date:  2002-05-15       Impact factor: 2.373

8.  The prevalence of cancer. Estimates based on the Connecticut Tumor Registry.

Authors:  A R Feldman; L Kessler; M H Myers; M D Naughton
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

9.  Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997.

Authors:  Jill S Barnholtz-Sloan; Andrew E Sloan; Ann G Schwartz
Journal:  J Neurosurg       Date:  2003-09       Impact factor: 5.115

10.  Long-term survival of children with brain tumors.

Authors:  D Jenkin
Journal:  Oncology (Williston Park)       Date:  1996-05       Impact factor: 2.990

View more
  120 in total

Review 1.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

2.  Combined local blood-brain barrier opening and systemic methotrexate for the treatment of brain tumors.

Authors:  Itzik Cooper; David Last; David Guez; Shirley Sharabi; Shirin Elhaik Goldman; Irit Lubitz; Dianne Daniels; Sharona Salomon; Gregory Tamar; Tzur Tamir; Ronni Mardor; Mati Fridkin; Yoram Shechter; Yael Mardor
Journal:  J Cereb Blood Flow Metab       Date:  2015-02-11       Impact factor: 6.200

3.  Neuropsychological and socioeconomic outcomes in adult survivors of pediatric low-grade glioma.

Authors:  M Douglas Ris; Wendy M Leisenring; Pamela Goodman; Chongzhi Di; Jennie Noll; Wendy Levy; Leslie L Robison; Gregory T Armstrong
Journal:  Cancer       Date:  2019-06-24       Impact factor: 6.860

4.  Relaxation-compensated amide proton transfer (APT) MRI signal intensity is associated with survival and progression in high-grade glioma patients.

Authors:  Daniel Paech; Constantin Dreher; Sebastian Regnery; Jan-Eric Meissner; Steffen Goerke; Johannes Windschuh; Johanna Oberhollenzer; Miriam Schultheiss; Katerina Deike-Hofmann; Sebastian Bickelhaupt; Alexander Radbruch; Moritz Zaiss; Andreas Unterberg; Wolfgang Wick; Martin Bendszus; Peter Bachert; Mark E Ladd; Heinz-Peter Schlemmer
Journal:  Eur Radiol       Date:  2019-02-26       Impact factor: 5.315

Review 5.  Treatment of Glioblastoma in the Elderly.

Authors:  Rebecca A Harrison; John F de Groot
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

Review 6.  Glutamate transporters in the biology of malignant gliomas.

Authors:  Stephanie M Robert; Harald Sontheimer
Journal:  Cell Mol Life Sci       Date:  2013-11-27       Impact factor: 9.261

Review 7.  Glutamate and tumor-associated epilepsy: glial cell dysfunction in the peritumoral environment.

Authors:  Susan C Buckingham; Stefanie Robel
Journal:  Neurochem Int       Date:  2013-02-04       Impact factor: 3.921

8.  Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.

Authors:  Liliana Soroceanu; Ryuichi Murase; Chandani Limbad; Eric Singer; Juanita Allison; Isabel Adrados; Rumi Kawamura; Arash Pakdel; Yayoi Fukuyo; Daniel Nguyen; Sabeena Khan; Robert Arauz; Garret L Yount; Dan H Moore; Pierre-Yves Desprez; Sean D McAllister
Journal:  Cancer Res       Date:  2012-12-13       Impact factor: 12.701

9.  Impact of perfusion map analysis on early survival prediction accuracy in glioma patients.

Authors:  Benjamin Lemasson; Thomas L Chenevert; Theodore S Lawrence; Christina Tsien; Pia C Sundgren; Charles R Meyer; Larry Junck; Jennifer Boes; Stefanie Galbán; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

10.  The effects of radiotherapy on psychosocial and cognitive functioning in adults with a primary brain tumor: a prospective evaluation.

Authors:  Maria Kangas; Robyn L Tate; Janet R Williams; Robert I Smee
Journal:  Neuro Oncol       Date:  2012-10-11       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.